Gelens Marielle A C J, Christiaans Maarten H L, van Hooff Johannes P
Department of Internal Medicine, Subdivision Nephrology, University Hospital Maastricht, 6202 AZ Maastricht, The Netherlands.
Nephrol Dial Transplant. 2008 Feb;23(2):701-6. doi: 10.1093/ndt/gfm544. Epub 2007 Nov 13.
Tacrolimus is more diabetogenic than cyclosporine. However, this difference is only discernible in the first few months after renal transplantation. In randomized trials, investigating the effects of immunosuppression after renal transplantation, no increase in diabetes mellitus has been reported. However, no sensitive technique was used in these trials, so subclinical alteration of glucose metabolism cannot be excluded.
We, therefore, decided to use an intravenous glucose tolerance test (IV-GTT), to investigate whether conversion from cyclosporine-based immunosuppression, with a median trough level of 120 microg/l, to tacrolimus-based immunosuppression with a median trough level of 6.5 microg/l influences glucose metabolism and whether patients on steroids behave differently from those not on steroids.
Thirty stable, non-diabetic patients, transplanted 10 or more years earlier, were converted from cyclosporine to tacrolimus without changing their concomitant medication. IV-GTT's were performed before and 2.5 months after the conversion. Before conversion, 40% of the patients had an abnormal glucose disappearance rate (kG): in 7%, kG was below 0.8 (abnormal range) and in 34%, kG was between 0.8 and 1.2 (indeterminate range). After conversion, stimulated insulin production, kG, HbA1C and fasting glucose did not change significantly. Insulin resistance (HOMA-R) of the whole group increased significantly, mainly due to a rise in HOMA-R in patients on steroids (n = 18). None of these patients developed overt diabetes mellitus.
Some 40% of long-term cyclosporine-treated patients had an abnormal glucose metabolism. Conversion from cyclosporine to tacrolimus does not negatively influence stimulated glucose metabolism or insulin resistance in stable, steroid-free renal transplant recipients. However, in patients receiving steroids, conversion leads to an increase in insulin resistance while insulin output remains the same.
他克莫司比环孢素更易引发糖尿病。然而,这种差异仅在肾移植后的最初几个月内可察觉。在肾移植后免疫抑制作用的随机试验中,未报告糖尿病发病率增加。然而,这些试验未采用敏感技术,因此不能排除葡萄糖代谢的亚临床改变。
因此,我们决定采用静脉葡萄糖耐量试验(IV-GTT),以研究将环孢素为基础的免疫抑制(中位谷浓度为120微克/升)转换为他克莫司为基础的免疫抑制(中位谷浓度为6.5微克/升)是否会影响葡萄糖代谢,以及服用类固醇的患者与未服用类固醇的患者表现是否不同。
30例稳定的非糖尿病患者,在10年或更早之前接受移植,从环孢素转换为他克莫司,同时不改变其伴随用药。在转换前和转换后2.5个月进行IV-GTT。转换前,40%的患者葡萄糖消失率(kG)异常:7%的患者kG低于0.8(异常范围),34%的患者kG在0.8至1.2之间(不确定范围)。转换后,刺激的胰岛素分泌、kG、糖化血红蛋白(HbA1C)和空腹血糖均无显著变化。整个组的胰岛素抵抗(HOMA-R)显著增加,主要是由于服用类固醇的患者(n = 18)HOMA-R升高。这些患者均未发生显性糖尿病。
约40%长期接受环孢素治疗的患者存在异常葡萄糖代谢。从环孢素转换为他克莫司对稳定的、未服用类固醇的肾移植受者的刺激葡萄糖代谢或胰岛素抵抗没有负面影响。然而,在接受类固醇治疗的患者中,转换会导致胰岛素抵抗增加,而胰岛素分泌保持不变。